---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-050541"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-11-06T22:28:31+00:00"
generated_at: "2026-11-06T22:30:08.038968+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q3 revenue falls to $1.1M; net loss widens to $5.3M despite CyPath unit sales doubling

## Summary
- Q3 2026 total revenue was ~$1.1M vs ~$1.4M a year ago; CyPath Lung testing revenue for the first nine months rose 79% to ~$1.1M.
- Net loss was ~$5.3M vs ~$5.1M in Q3 2025; operating loss widened to ~$3.5M from ~$2.3M, with operating expenses ~$4.6M vs ~$3.7M.
- CyPath Lung unit sales rose 100% through Q3 vs the first nine months of 2025; ordering physicians increased 89% YoY and existing-physician volume rose 48%.
- Cash was ~$2.6M at Sept. 30 vs ~$6.4M at Dec. 31, 2025; the company raised $8.0M gross in August and October 2026 offerings, including ~$4.0M after quarter-end.
- Signed an AvMEDICAL distribution agreement targeting VA/government channels; 11 clinical trial sites are active, including nine VA/military centers; patent portfolio has 22 awarded and 36 pending.

## SEC filing metadata
- accession: 0001493152-26-050541
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-11-06T22:28:31+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226050541/0001493152-26-050541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226050541/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-050541
- JSON: https://secwatch.observer/filing/0001493152-26-050541.json
- Plain text: https://secwatch.observer/filing/0001493152-26-050541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.